Skip to main content
. 2018 Aug 29;19(9):2565. doi: 10.3390/ijms19092565

Table 2.

Myeloid cell contributions to cancer therapy refractoriness.

Chemotherapy Radiotherapy Antiangiogenic Therapy Immunotherapy
Facilitate angiogenic-revascularization

Formation of abnormal tumor vasculature-impede drug delivery, accentuate hypoxic environment
Facilitate vasculogenic-revascularization Facilitate VEGFA-independent angiogenic-revascularization Secretion of VEGFA

Formation of abnormal tumor vasculature-impede drug delivery, accentuate hypoxic environment